Evolving Concepts in Anterior Segment Outcomes: Comanaging P -

Name: Evolving Concepts in Anterior Segment Outcomes: Comanaging Premium IOL Patients Podcast
Uploaded: 2020-06-22T08:00:00+00:00
Duration: 28 min 42 s
Description: In this audio interview, Marc Bloomenstein, OD and Justin Schweitzer, OD discuss comanaging premium intraocular lens patients. How do you talk to patients

Media formats available:

Details

Presenters

Overview
In this audio interview, Marc Bloomenstein, OD and Justin Schweitzer, OD discuss comanaging premium intraocular lens patients. How do you talk to patients about presbyopia-correcting and toric IOLs before surgery? What instruments do you rely on to accurately assess preoperative patients? How do you handle difficult patients? How do you address postoperative residual astigmatism?
Supported by unrestricted educational grants from Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision
Learning Objectives
- Describe and identify current and emerging presbyopia and astigmatism correcting IOLs
- Describe elements of a standardized postoperative outcomes assessment for patients with presbyopia and/or astigmatism correcting IOLs
- Cite literature on the impact of rotational error on the quality of vision and patient satisfaction in toric IOL patients
Accreditation
This podcast has no credit associated with it.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty have the following financial relationships with commercial interests:
Marc R. Bloomenstein, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, OcuSoft, Reichert, and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, and Sun Pharma. Research/Grant Support: Allergan. Stock/Shareholder: Tearlab.
Justin Schweitzer, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aerie, Alcon, Allergan, Bausch + Lomb, EyePoint, Glaukos, Horizon, Johnson & Johnson Vision, Ocular Therapeutix, Quidel, Reichert, Sight Sciences, and Sun Pharma. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, and Johnson & Johnson Vision.Stock/Shareholder:Equinox.
EDITORIAL DISCLOSURES
Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Carl Zeiss Meditec, Inc., Glaukos, or Johnson & Johnson Vision.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 06/22/2020
Expiration Date: 06/30/2021